Noteworthy

Nov 15, 2018
Like Facebook, many healthcare companies are trying to become more "like people". They should instead prioritize transparency and engaging in knowledge-sharing with the public, writes Julia Stern.
Nov 14, 2018
Pharmaceutical Executive
The increase in new drug approvals and candidates in development are good signs for pharma & biotech, but both sectors face continued pricing, cost, and policy-related challenges, writes Peter Young.
Nov 14, 2018
Pharmaceutical Executive
Regulators, prosecutors shifting enforcement focus from off-label promotion to messages that raise safety issues, mislead. Jill Wechsler reports.
Nov 13, 2018
Emil Eifrem examines how researchers at Munich’s German Center for Diabetes Research are uncovering insights with a new way of working with complex data.
Nov 13, 2018
Pharmaceutical Executive
Amid a still-difficult environment for enforcing cannabis-related patents, Eric Furman and Ari Feinstein explore the types of patent protection available for cannabis-based therapies and inventions.
Nov 02, 2018
FDA's proposal to gather real-world evidence from 10 million individuals could have profound implications, but the Agency needs to take a more expansive view of what RWE can be, writes Paul Glimcher.
Nov 01, 2018
Bruno Delagneau reviews the current landscape for price-setting in the US and suggests that it’s time for pharma to change their practices.
Oct 29, 2018
Pharmaceutical Executive
The next generation of supply chain shows an increasing need for blockchain technology.
Oct 27, 2018
Eli Lilly's Michael W. Magdycz share some of the lessons he's learned directing alliances spanning a range of countries and products.
Oct 26, 2018
Pharmaceutical Executive
How three of the top MBA programs in the US prepare their students for pharma success.
native1_300x100
lorem ipsum